Chimeric Fc Receptor Amplification Modules for ADCC
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The body's natural ADCC response is limited by low affinity Fc receptors and inhibitory pathways, leading to inadequate proliferation and survival of effector cells, which restricts its effectiveness in targeting and eliminating diseased cells, such as cancer cells.
Innovation Solution
A synthetic biology approach is developed to enhance the ADCC response by creating a high-affinity Fc receptor and incorporating amplification modules to promote the proliferation and survival of immune effector cells, using genetic constructs that encode chimeric receptors with improved binding affinity and intracellular signaling domains.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If endogenous NK cells mediate ADCC response, then the immune system can recognize and eliminate diseased cells, but the response is limited by low affinity Fc receptors and rapid cell death
Solution Approach 1:
The patent modifies the Fc receptor affinity parameter by creating chimeric receptors with higher affinity for antibody Fc regions. This parameter change allows effector cells to bind more strongly to antibody-coated target cells, enhancing ADCC response durability and effectiveness without relying on endogenous low-affinity receptors
Solution Approach 2:
The patent creates composite immune effector cells by introducing exogenous genes encoding chimeric Fc receptors and amplification modules into NK cells or other immune cells. This composite approach combines enhanced receptor affinity with proliferation capabilities, resulting in cells that both recognize targets effectively and survive longer to mediate sustained ADCC response
2Measurement precision
If high-affinity Fc receptors are engineered, then binding sensitivity to antibody-coated cells improves, but the complexity of the immune effector cell increases
Solution Approach 1:
The patent segments the Fc receptor structure into distinct functional domains (Fc-binding domain from CD64, transmembrane domain from CD16, signaling domain from CD3zeta) and recombines them into a chimeric receptor. This segmentation allows optimization of each domain's function while maintaining overall receptor functionality, achieving high affinity without excessive complexity
Solution Approach 2:
The patent uses chimeric Fc receptors as intermediary structures that bridge antibody recognition and immune cell activation. These engineered receptors serve as mediators that translate antibody binding into potent ADCC signals, simplifying the overall immune response mechanism while enhancing sensitivity
3Quantity of substance
If amplification modules are added to promote effector cell proliferation, then the quantity of ADCC effector cells increases, but the genetic construct complexity increases
Solution Approach 1:
The patent incorporates proliferation signals and amplification modules into the genetic construct before effector cell introduction. This preliminary action ensures that effector cells are pre-programmed with the capability to self-amplify upon encountering target cells, eliminating the need for external proliferation support during treatment
Solution Approach 2:
The patent designs amplification modules that serve multiple functions: enhancing effector cell proliferation, improving survival, and potentially increasing cytotoxic activity. This multi-functionality reduces the need for separate genetic constructs for each function, thereby managing complexity while achieving multiple therapeutic goals
Data Source
AI summary
A novel synthetic biology-based ADCC technology is provided that enhances or enables ADCC response. The novel ADCC technology can be used to prevent or treat cancers, infectious, inflammatory or autoimmune diseases, and other diseases where elimination of diseased cells is desirable.